文献速递基础与转化研究临床试验与 GCP

供者骨髓联合受者调节性T细胞在肾移植中无需照射诱导嵌合

Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation.
PubMed 文献 · Sci Transl Med · 2026-06-17

这项1/2a期对照试验在HLA错配活体供肾移植中联合输注受者多克隆调节性T细胞与供者骨髓细胞,研究组全部检出供者嵌合,对照组均未检出,主要终点达成(P=0.001),且部分患者免疫抑制可减至贝拉西普单药。

要点

  • 联合输注供者骨髓与受者调节性T细胞可在不照射条件下诱导供者嵌合。
  • 研究组嵌合水平显著高于对照组,主要终点达成(P=0.001)。
  • 部分研究组患者免疫抑制可减至贝拉西普单药治疗。

核心结论

  • 供者骨髓联合受者调节性T细胞可在肾移植中无需照射诱导基于嵌合的免疫调节。

研究设计与样本

  • 控制性1/2a期试验(NCT03867617),在HLA错配活体供肾移植中开展。
  • 研究组6例患者移植后立即接受多克隆受者调节性T细胞与供者骨髓细胞。
  • 免疫抑制方案为胸腺球蛋白、贝拉西普、西罗莫司、激素及短程托珠单抗。
  • 对照组不接受调节性T细胞、骨髓细胞或托珠单抗。

主要发现

  • 研究组全部患者移植后检出总白细胞供者嵌合,对照组均未检出。
  • 研究组嵌合水平高于对照组,主要终点达成(P=0.001)。
  • 嵌合见于多个谱系,T细胞中最高达4%。
  • 3例研究组患者免疫抑制可减至贝拉西普单药。
  • 体外T细胞增殖试验显示抗供者反应降低,T细胞受体测序显示研究组抗供者T细胞克隆扩增受抑。

临床怎么用

  • 该组合细胞疗法为肾移植中无需照射诱导嵌合提供了概念验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cotransplantation of donor bone marrow (BM) has yielded a therapeutic benefit in clinical trials of kidney transplantation by inducing chimerism-based tolerance, but this was dependent on unfavorable recipient irradiation. Additional regulatory T (Treg) cell administration can overcome the need for myelosuppression, but this has been demonstrated only in mice so far. Here, we conducted a controlled, phase 1/2a trial of combined BM and Treg cell therapy in HLA-mismatched living-donor kidney transplantation (NCT03867617). Six patients received polyclonal recipient Treg cells and donor BM cells (BMCs) immediately posttransplant. Immunosuppression consisted of thymoglobulin, belatacept, sirolimus, steroids, and short-course tocilizumab. The control group received no Treg cells, BMCs, or tocilizumab. Total leukocyte donor chimerism was detected across all patients in the study group posttransplantation. This was not observed in any patient belonging to the control group, consequently meeting the primary end point of higher chimerism levels in the study versus control groups (P = 0.001). Chimerism was observed across multiple lineages, with up to 4% in T cells. For three patients in the study group, immunosuppression could be minimized to belatacept monotherapy. Antidonor reactivity was decreased in in vitro T cell proliferation assays, suggesting specific downmodulation of the antidonor T cell response. In addition, expansion of antidonor T cell clones was shown by T cell receptor sequencing analysis to be dampened in the study versus control groups. This trial serves as a proof of concept for a combination cell therapy that induces chimerism-based immunomodulation in kidney transplantation without the need for irradiation.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Wekerle T, Muckenhuber M, Heinzel A, et al. Donor bone marrow together with recipient regulatory T cells induces chimerism without irradiation in kidney transplantation. Sci Transl Med. 2026. PMID: 42308328. doi:10.1126/scitranslmed.aee6850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。